| Literature DB >> 29200009 |
Jerrold H Levy1, Andreas Koster, Quintin J Quinones, Truman J Milling, Nigel S Key.
Abstract
Fibrinolysis is a physiologic component of hemostasis that functions to limit clot formation. However, after trauma or surgery, excessive fibrinolysis may contribute to coagulopathy, bleeding, and inflammatory responses. Antifibrinolytic agents are increasingly used to reduce bleeding, allogeneic blood administration, and adverse clinical outcomes. Tranexamic acid is the agent most extensively studied and used in most countries. This review will explore the role of fibrinolysis as a pathologic mechanism, review the different pharmacologic agents used to inhibit fibrinolysis, and focus on the role of tranexamic acid as a therapeutic agent to reduce bleeding in patients after surgery and trauma.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29200009 PMCID: PMC5811331 DOI: 10.1097/ALN.0000000000001997
Source DB: PubMed Journal: Anesthesiology ISSN: 0003-3022 Impact factor: 7.892